Horizon Pharma (NASDAQ:HZNP) was upgraded by equities researchers at Mizuho from a “neutral” rating to a “buy” rating in a report issued on Friday, The Fly reports.
Several other equities analysts have also recently issued reports on the company. Cantor Fitzgerald set a $17.00 target price on Horizon Pharma and gave the company a “buy” rating in a research note on Monday. ValuEngine cut Horizon Pharma from a “buy” rating to a “hold” rating in a research note on Sunday, December 31st. BidaskClub raised Horizon Pharma from a “hold” rating to a “buy” rating in a research note on Friday, December 22nd. UBS Group set a $20.00 target price on Horizon Pharma and gave the company a “buy” rating in a research note on Thursday, November 30th. Finally, Jefferies Group boosted their target price on Horizon Pharma from $16.00 to $21.00 and gave the company a “buy” rating in a research note on Tuesday, November 7th. One research analyst has rated the stock with a sell rating, two have given a hold rating and twelve have issued a buy rating to the company’s stock. Horizon Pharma presently has an average rating of “Buy” and a consensus target price of $18.75.
Horizon Pharma (NASDAQ:HZNP) opened at $15.09 on Friday. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.64 and a quick ratio of 1.52. The company has a market capitalization of $2,490.00, a P/E ratio of -4.96, a price-to-earnings-growth ratio of 0.73 and a beta of 1.30. Horizon Pharma has a 12 month low of $9.45 and a 12 month high of $17.69.
A number of institutional investors have recently added to or reduced their stakes in the business. Beacon Capital Management bought a new stake in Horizon Pharma in the fourth quarter worth $0. Assetmark bought a new stake in Horizon Pharma in the third quarter worth $0. Profund Advisors LLC boosted its holdings in Horizon Pharma by 0.8% in the first quarter. Profund Advisors LLC now owns 13,508 shares of the biopharmaceutical company’s stock worth $200,000 after acquiring an additional 112 shares in the last quarter. First Mercantile Trust Co. boosted its holdings in Horizon Pharma by 2.7% in the first quarter. First Mercantile Trust Co. now owns 11,770 shares of the biopharmaceutical company’s stock worth $174,000 after acquiring an additional 310 shares in the last quarter. Finally, US Bancorp DE boosted its holdings in Horizon Pharma by 1.2% in the first quarter. US Bancorp DE now owns 32,050 shares of the biopharmaceutical company’s stock worth $473,000 after acquiring an additional 368 shares in the last quarter. 86.58% of the stock is currently owned by institutional investors and hedge funds.
WARNING: This story was published by American Banking and Market News and is owned by of American Banking and Market News. If you are reading this story on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this story can be read at https://www.americanbankingnews.com/2018/01/12/horizon-pharma-hznp-upgraded-to-buy-by-mizuho.html.
Horizon Pharma Company Profile
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
